Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Poxel Reports Revenue for the Third Quarter of 2026

businesswire.com
SCYX Scynexis is mentioned as acquiring PXL770 from Poxel for potential consideration up to $196 million, including an upfront payment and milestone payments. The article does not provide specific details on Scynexis's performance or outlook.

Poxel Reports Revenue for the Third Quarter of 2026 LYON, France--( BUSINESS WIRE)--Regulatory News:

POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announces its revenue for the third quarter ended September 30, 2026, and for the first nine months of the fiscal year.

Commercial Activity Update

TWYMEEG ® (Imeglimin)

Consolidated Revenue for the Third Quarter and the First Nine Months of 2026

EUR (in thousands)

Q3 2026

Q3 2025

9M 2026

9M 2025

3 months

3 months

9 months

9 months

Royalties from the Sumitomo Pharma agreement

1,629

1,047

4,131

3,128

Retroactive royalty adjustments

322

245

322

480

Other

-

-

-

-

Total consolidated revenue

1,951

1,292

4,453

3,608

* Unaudited figures. The 2025 figures are presented as published in the press release dated February 11, 2026, including retroactive adjustments to royalties for the second and third quarters of 2025.

Consolidated Cash and Cash Equivalents

As of September 30, total consolidated cash and cash equivalents amounted to €388k.

EUR (in thousands)

Q3 2026

Q2 2026

Q1 2026

Cash

388

1,510

245

Cash equivalents

-

-

-

Total cash and cash equivalents

388

1,510

245

About Poxel

Poxel is an international biopharmaceutical company at the commercial and clinical development stage, specialized in the development of innovative treatments for severe chronic diseases with metabolic pathophysiology, including rare metabolic diseases and hypertrophic cardiomyopathy (HCM).

TWYMEEG ® (Imeglimin), Poxel's first product targeting mitochondrial dysfunction, is marketed in Japan for the treatment of type 2 diabetes by Sumitomo Pharma, and Poxel expects to receive royalties and sales-based payments. Poxel has entered a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.

For the treatment of MASH, PXL065, a deuterium-stabilized R-pioglitazone, achieved its primary endpoint in the Phase 2 DESTINY-1 study.

PXL770 is focused on rare diseases, notably autosomal dominant polycystic kidney disease (ADPKD). On March 31, 2026, Poxel announced the divestment of PXL770 to Scynexis for a total potential consideration of up to $196 million. The Company received an upfront payment of $8 million, with additional near-term development milestone payments of up to $8 million and up to $180 million in commercial milestone payments. Scynexis will develop PXL770 in its potential ADPKD indications.

Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release concerning future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, but are not limited to, any statements preceded by, followed by, or including words such as ‘objective,’ ‘believe,’ ‘expect,’ ‘aim,’ ‘intend,’ ‘may,’ ‘anticipate,’ ‘estimate,’ ‘plan,’ ‘project,’ ‘will,’ ‘could,’ ‘likely,’ ‘should,’ and other words and terms of similar meaning, or the negative form of these words and terms. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to differ materially from the results or performance expected, expressed or implied in such forward-looking statements. Actual events or results may differ from those described in this document due to a number of risks or uncertainties described in the Company's 2024 Universal Registration Document available on the Company's website and that of the AMF ( https://www.amf-france.org/fr). The Company does not endorse and is not responsible for the content of external hyperlinks mentioned in this press release.

Glossary

For the sake of clarity and transparency, below is a list of words and/or expressions used in this press release or in other communications from Poxel:

1 Converted at the JPY-EUR exchange rate of 178.28 as of September 30, 2026

2 Sumitomo Pharma's fiscal year 2026 begins on April 1, 2026

3 Sumitomo Pharma's fiscal year 2026 ends on March 31, 2027